

06:00 16 Apr 2019

BioPorto names Amy Winslow president of US subsidiary as it prepares FDA applications

BioPorto A/S (CPH:BIOPOR) named Amy Winslow president of its US subsidiary, BioPorto Diagnostics Inc, as it prepares FDA applications for a new kidney diagnostic test, the Denmark company announced Monday.

Before joining BioPorto, which provides diagnostic tests and antibodies to health care professionals, Winslow was president and CEO of Magellan Diagnostics, a point-of-care company based in Boston. She increased its profitability and ultimately led a sale of the company.

Prior to that, she served as VP of marketing at Athena Diagnostics, a neurodiagnostic medical laboratory.

WATCH: BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test

"I am pleased to welcome Amy to BioPorto's leadership team," CEO Peter Eriksen said. "As we prepare for FDA clearance of The NGAL Test, it is critical to establish a strong presence in the US to deliver rapid growth. Amy will lead this charge."

The NGAL Test is designed to detect acute kidney injury by measuring NAGL levels, a biomarker which increases in response injury, as much as 24 hours before it would otherwise be detectable.

BioPorto expects to submit two regulatory clearance applications for the test to the FDA in 2019, one in the first half of the year for clinical use in children under 21 and one in the second half of the year for use in adults.

The Copenhagen-listed stock closed up 1.4% to 3.92 kroner.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Share Information

Code: BIOPOR

Listing: NASDAQ OMX

Sector: Pharma & Biotech

Website: www.bioporto.com

Company Synopsis:

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).